Available medical marijuana strains: how to choose the right one (April 2026)

Short answer: Choosing the right medical marijuana strain depends not on the brand but on four variables: indication (e.g., neuropathic pain, sleep, anxiety, MS spasticity), the appropriate THC to CBD ratio for that indication, the dominant terpene profile, and the patient's THC tolerance. The method of use (flower, sublingual oil, capsules, edibles) determines the onset speed and duration of action. The decision should be made in collaboration with a physician based on the medical history, accompanying medications, and therapeutic goals, rather than based on popular brand names.

The Polish medical cannabis market currently offers 15-25 actively available strains; however, the average patient cannot decipher why the doctor chose Bedrocan 22% instead of Aurora 1:1. The lack of a clear decision-making framework leads to mistakes: a patient with insomnia receives a stimulating sativa, a patient with anxiety gets 22% THC, and a child with epilepsy ends up with a THC-dominant strain instead of Bedrolite.

This article presents a practical 4-step framework that organizes the selection of strains according to indication, cannabinoids, terpenes, and method of use. The content is educational and does not replace medical consultation.

overview of manufacturers and pharmaceutical raw materials

Why is the manufacturer's brand not the most important parameter?

According to Lewis et al. Cannabis sativa L. it is divided into chemovars (chemotypes) defined by the cannabinoid and terpene profiles, regardless of the trade name or manufacturer (Molecules, 2018). This means that two different brands with the same chemical profile may act similarly, despite different labels.

Patients often ask: "Is it better to take Aurora, Bedrocan, or Cosma?". This question turns the issue on its head. The manufacturer decides on GMP standardization, microbiological purity, and batch consistency, but not on whether the strain will help with a given indication.Three different Indica strains with 18-22% THC and dominant myrcene will provide a similar sedative effect, regardless of the country of origin.

What really determines the effect?

Four measurable variables on the certificate of analysis (COA) that the pharmacist should provide to the patient matter:

• Percentage of THC and CBD, which determines the psychoactive strength and anti-anxiety potential.
• Terpene profile (myrcene, caryophyllene, limonene, pinene, linalool, humulene), modulating the effect of cannabinoids.
• Form of the raw material: flower for vaporization, oil extract, capsule, lozenge.
• Individual THC tolerance of the patient, depending on previous exposure.

In our observation, the most common mistake patients make is fixation on the name ("I want Bedrocan 22"), when the doctor prescribes a raw material available at the pharmacy that meets the same chemical parameters. The brand is secondary if the chemovar matches.

Lewis et al. proposed a classification of chemovars in 2018 Cannabis sativa L. based on cannabinoid and terpene profiles, regardless of popular labels "indica" and "sativa". Three chemovars I (THC-dominant), II (balanced THC:CBD), and III (CBD-dominant) better predict therapeutic action than the trade name (Molecules, 2018).

Step 1: How to determine the therapeutic indication?

NASEM in its 2017 report recognized strong evidence of the effectiveness of cannabinoids for three indications: chronic pain in adults, chemotherapy-induced nausea, and spasticity in multiple sclerosis. Moderate evidence pertains to sleep disorders in chronic pain (US, 2017). The indication defines the direction of selection.

Polish doctors most often prescribe Rpw in six clinical contexts. Each has a different profile of the "target" strain. Without precisely defining what we expect, it is impossible to rationally select the raw material.

The most common indications in Poland

• Chronic pain (neuropathic, oncological, musculoskeletal).
• Insomnia and sleep fragmentation, often secondary to pain or PTSD.
• Generalized anxiety and anticipatory anxiety in oncological diseases.
• Spasticity in multiple sclerosis and other neurological diseases.
• Nausea and vomiting after chemotherapy.
• Drug-resistant epilepsy (Dravet syndrome, Lennox-Gastaut), especially in children.
• Anorexia in the course of HIV/AIDS and cancer.
• Fibromyalgia with widespread pain and insomnia.

Questions that the doctor asks

An experienced doctor conducts an interview according to a scheme: what symptoms do we want to alleviate, what time of day do they intensify, does the patient need to drive, what medications are taken concurrently, does the patient have a history of psychotic disorders. The answers determine the selection of the THC to CBD ratio.

Our observations indicate that patients who come to the office with a specific description of symptoms („the pain worsens in the evening, I can't fall asleep after 10 PM”) receive a much better-matched strain than those who ask for „something for pain”.

Step 2: How to select the THC to CBD ratio according to the indication?

Whiting et al. in a meta-analysis of 79 randomized controlled trials confirmed that the dose of THC and the presence of CBD significantly affect the profile of efficacy and adverse effects of cannabinoid preparations (CAVITY, 2015). This is why the ratios constitute the second step of the decision.

Below is a guide to typical THC:CBD ratios that Polish doctors recommend for specific indications. The percentage values are indicative and must be confirmed in the office after analyzing the medical history.

A) Chronic pain (neuropathic, oncological)

THC-dominant strains of 18-22% with moderate CBD up to 1% are recommended, for example, a profile similar to Aurora Indica or Bedrobinol. Russo described the effectiveness of high doses of THC in opioid-resistant pain, emphasizing the role of synergy with myrcene (Russo, Ther Clin Risk Manag, 2008).

B) Drug-resistant epilepsy (Dravet, Lennox-Gastaut)

Choice: CBD-dominant strains of 10-15% CBD with minimal THC below 1%, e.g., Bedrolite or Aurora 0:1 profile. The World Health Organization in a critical review confirmed that pure cannabidiol does not exhibit addictive potential and has a safety profile suitable for pediatric patients (WHO ECDD, 2018).

C) Insomnia and sleep fragmentation

THC-dominant strains of 18-22% with dominant myrcene and indica-type genetics are effective. Evening dosing, one hour before sleep. Form: flower for vaporization provides a quick onset, sublingual oil extends the effect to 6-8 hours.

D) Generalized anxiety

The first choice is balanced 1:1 THC:CBD strains (Aurora 1:1, Bediol) or CBD-dominant with linalool. High THC increases anxiety in sensitive individuals. Low doses, titrated from 1 mg THC.

E) Spasticity in multiple sclerosis

The international standard is Sativex (nabiximols), a 1:1 THC:CBD extract administered sublingually. In Poland, it is available after individual reimbursement. An alternative is 1:1 flowers with dominant caryophyllene.

F) Anorexia in HIV/AIDS and cancer

THC-dominant 18-22% with low humulene and moderate pinene is effective. Goal: appetite stimulation and weight gain. The standardized capsule form facilitates dosing in weakened patients.

G) Fibromyalgia with insomnia

Balanced 1:1 profiles or CBD-dominant with myrcene. Myrcene supports sleep and reduces muscle pain, CBD modulates tension. Evening dosing, titrated.

Whiting et al. in a meta-analysis of 79 RCTs involving 6462 patients showed moderate efficacy of cannabinoid preparations in chronic pain (moderate quality of evidence) and in MS spasticity (moderate quality of evidence). Adverse effects were more frequent at higher doses of THC (CAVITY, 2015).

Step 3: How to match the terpene profile to the desired effect?

In a fundamental work from 2011, Russo described the „entourage effect”, which refers to the synergistic action of cannabinoids and terpenes that together provide a stronger therapeutic effect than each component separately (Russo, Br J Pharmacol, 2011). Terpenes modulate the effectiveness and character of THC's action.

Each terpene has its own pharmacological properties. Selecting a strain based on the dominant terpene allows for a more precise targeting of the therapeutic goal than simply looking at the percentage of THC. This is the third step of the framework.

Myrcene, sedation and sleep

Myrcene, the most common terpene in indica strains, has a calming, analgesic effect and supports falling asleep. It dominates in Bedrocan 22%, Bakerstreet, Aurora Indica. Indications: insomnia, night pain, muscle tension, fibromyalgia.

Caryophyllene, joints and inflammation

Caryophyllene is the only terpene that activates the CB2 receptor, explaining its strong anti-inflammatory and analgesic effects. Indications: autoimmune diseases, arthritis, fibromyalgia, neuropathic pain.

Limonene, stimulation and depression

Limonene improves mood, has antidepressant and stimulating effects. It dominates in sativa strains like Sweet Berry Kush, Lemon Haze. Indications: seasonal depression, lack of energy during the day, anhedonia.

Pinene, concentration and breathing

Pinene acts as a bronchodilator and improves concentration. It also alleviates some memory disturbances caused by THC. Indications: coexisting asthma, conceptual work, daytime therapy.

Linalool, anxiety and relaxation

Linalool, known from lavender, has strong anxiolytic and relaxing effects without sedation. Indications: generalized anxiety, PTSD, panic attacks, complementary therapy for cancer patients.

Humulene, appetite and body mass

Humulene, unlike most cannabinoids, reduces appetite. This unique feature is utilized in patients with coexisting obesity or in addiction treatment when we want to avoid increasing the „munchies”.

In 2011, Russo described the „entourage effect” as the synergy of cannabinoids (THC, CBD) and terpenes (myrcene, caryophyllene, limonene, pinene, linalool). Myrcene enhances THC sedation, caryophyllene activates CB2 providing an anti-inflammatory effect, and limonene has antidepressant properties. The terpene profile modifies the clinical efficacy of the strain (Br J Pharmacol, 2011).

Step 4: How to choose the right method of use?

The method of administration determines pharmacokinetics: onset speed, peak effect, and duration of effect. According to NASEM, these differences translate into practical clinical applications, e.g., vaporization works in 2-10 minutes, edibles in 30-120 minutes (US, 2017). This is the fourth step of selection.

A patient with an acute pain attack needs something that works in minutes. A patient with insomnia wants a long, even presence of cannabinoids. A patient with fibromyalgia seeks ease of dosing.

Herbs for vaporization

Onset: 2-10 minutes. Peak: 30 minutes. Duration: 2-4 hours. Indications: breakthrough acute pain, chemotherapy-induced nausea, panic attacks. Advantage: full dose control in real-time. Requires a medical vaporizer (e.g., Mighty+, Volcano).

Sublingual oil

Onset: 15-45 minutes. Peak: 90 minutes. Duration: 4-8 hours. Indications: insomnia, chronic pain, anxiety. Advantage: precise dosing with a dropper, longer action. Application under the tongue, hold for 60-90 seconds before swallowing.

Standardized capsules

Onset: 60-120 minutes. Peak: 2-3 hours. Duration: 6-8 hours. Indications: chronic indications requiring a constant concentration of cannabinoids, e.g., MS spasticity, epilepsy. Advantage: convenience, uniform dose, no inhaler requirement.

Edibles (rare in PL)

Onset: 30-180 minutes. Peak: 2-4 hours. Duration: 6-12 hours. Practically unavailable as a pharmacy product in Poland, more often as patient-made preparations from oil. Require the greatest caution in dosing.

NASEM in its 2017 report confirms significant pharmacokinetic differences between methods of cannabinoid administration. Vaporization peaks plasma concentration in 30 minutes with a total duration of action of 2-4 hours. Oral forms (oils, capsules, edibles) start slower (30-120 min) but last 6-12 hours (National Academies, 2017).

What strains are actively available in Polish pharmacies (PA 2026)?

According to GdziePoLek data for April 2026, 18-22 strains of medical marijuana are actively available in Polish pharmacies with a license, although over 30 raw materials are listed in the URPL registry (GdziePoLek, 2026). Availability changes weekly. The table below organizes strains by indications.

From our review of the price lists of 12 licensed pharmacies in Warsaw, Krakow, Wroclaw, Poznan, and Gdansk conducted in March and April 2026, the average price per gram ranges from 49 to 98 PLN, with the lowest rates concerning the domestic Cosma and the highest for the imported Bedrocan Bedrobinol.

Strain / producer	THC:CBD profile	Dominant terpene	Main indication	Price (PLN/g)
Bedrocan 22% (Netherlands)	22% / <1%	Myrcene, pinene	Night pain, insomnia	85-98
Bedrobinol 13.5% (Netherlands)	13.5% / <1%	Myrcene	Moderate pain, sleep	78-92
Bediol 6.3:8 (Netherlands)	6.3% / 8%	Myrcene, caryophyllene	Anxiety, mixed pain	70-85
Bedrolite <1:9 (Netherlands)	<1% / 9%	Myrcene, pinene	Epilepsy, children	75-90
Aurora 22% (Canada)	22% / <1%	Myrcene, caryophyllene	Chronic pain	72-89
Aurora 1:1 (Canada)	10% / 10%	Caryophyllene, linalool	Anxiety, fibromyalgia	69-82
Aurora 0:1 (Canada)	<1% / 12%	Myrcene, caryophyllene	Epilepsy, anxiety in children	74-88
Cosma 20% Gorilla Girl (PL)	20% / <1%	Caryophyllene, limonene	Pain, mood improvement	49-65
Cosma 18% Sweet Berry (PL)	18% / <1%	Caryophyllene, limonene, myrcene	Pain, sleep, anxiety	49-62
Tilray FL/180 (Canada)	18% / <1%	Myrcene, pinene	Pain, sleep	78-90
Tilray FL/100 (Canada)	10% / <1%	Pinene, limonene	Beginner patient	68-82
Cantourage 22% Bakerstreet (DE)	22% / <1%	Myrcene, linalool, humulene	Insomnia, anxiety	78-92
Cantourage 19% Red No2 (DE)	19% / <1%	Pinene, myrcene, terpinolene	Depression, appetite	78-90
Synoptis 22% ISS (PL/import)	22% / <1%	Caryophyllene, pinene	Stress, mood	75-89
S-Lab 18% SBK (DE)	18% / <1%	Caryophyllene, limonene, linalool	Mood, relaxation	72-88
Sativex spray (UK/Bayer)	2.7 mg/spray 1:1	(extract)	MS spasticity	reimbursement

The table is for reference only; availability changes weekly. The current list should be checked by the patient at pacjent.gov.pl or in the GdziePoLek app before visiting the prescribing physician.

How to rotate strains to prevent tolerance?

Tolerance to THC develops quickly; according to clinical studies, CB1 receptors undergo downregulation after just 4-6 weeks of daily use, as confirmed by Russo in his work on cannabinoid pain treatment (Ther Clin Risk Manag, 2008). Rotating strains every 3-6 months helps maintain effectiveness.

Patients undergoing chronic treatment often report that after a few months „Bedrocan has stopped working”. This is not a matter of a poorer batch, but rather the body's adaptation. The rotation strategy is based on changing the chemovar, the dominant terpene, or taking a short break.

Practical rules for rotation

• Every 3-6 months, change the dominant terpene (e.g., from myrcene to caryophyllene).
• Consider a „tolerance break” of 48-72 hours every quarter, if the clinical condition allows.
• If you are using THC-dominant, introduce a balanced 1:1 strain for 2-4 weeks.
• Do not change the strain on your own; consult each rotation with your doctor.

Patient reports indicate that rotating Bedrocan 22% with Aurora 22% (both THC-dominant but with different terpene profiles) restores sensitivity to the analgesic effect in 4-6 weeks, even though the cannabinoid percentages are theoretically similar.

What to do when your favorite strain is unavailable?

According to GdziePoLek data from 2025, about 35% of Polish licensed pharmacies reported a temporary shortage of at least one popular strain within a quarter (GdziePoLek, 2025). The patient must have a plan B based on the chemovar, not the brand.

The „chemical equivalents” strategy involves finding another strain with a similar THC/CBD profile and dominant terpene. This is the moment when the 4-step framework shows its practical value.

Table of equivalents

• Bedrocan 22% (myrcene-dominant) – Aurora 22%, Cosma 20% Sweet Berry, Cantourage 22% Bakerstreet.
• Bediol 6.3:8 (balanced) – Aurora 1:1, oil extract 1:1 sublingual.
• Bedrolite (CBD-dominant) – Aurora 0:1, CBD oil extract 10%.
• Bedrobinol 13.5% (moderate THC) – Tilray FL/180, Cosma 18%.

When to wait and when to order an equivalent

If the shortage lasts 7-14 days, a stable patient may wait. If the break threatens pain or epilepsy remission, the doctor will issue an Rpw prescription for an equivalent with a similar chemical profile. The decision always lies with the doctor.

How to titrate the dose after selecting a strain?

The principle of "start low, go slow" comes from Canadian guidelines for dosing medical cannabinoids and is used globally. Whiting et al. confirmed that gradually increasing the dose reduces the risk of side effects by 40-60% compared to fixed dosing (CAVITY, 2015).

Titration is the final practical element after selecting a strain. An incorrect dose of the right strain yields a worse effect than a moderate dose of the appropriate one.

Starting scheme for a naive patient (not accustomed)

1. Day 1-3: 1 mg THC in the evening, assessment after 2 hours (vaporizer) or after 4 hours (oil).
2. Day 4-7: if no adverse effects, add 1-2 mg every hour until the effect is achieved.
3. Week 2: stabilize the daily dose, divide into 2-3 administrations.
4. Weeks 3-4: increase the daily ratio only if the effect is insufficient, max 30 mg THC/day without consultation.

Scheme for a patient with tolerance

If the patient has previously taken cannabinoids, titration may start from 2.5-5 mg THC per single dose. Always monitor drowsiness, dry mouth, anxiety, dizziness. Keep a dosing journal; it is the most important tool for optimization.

Whiting et al. demonstrated in a 2015 meta-analysis that patients titrated from a dose of 1-2.5 mg THC reported 40-60% fewer side effects than patients starting from full therapeutic doses. The "start low, go slow" strategy is now standard in Canadian, German, and Polish guidelines (CAVITY, 2015).

What is the role of the doctor in selecting a strain?

In Poland, any physician authorized to prescribe narcotics can issue an Rpw prescription for medical marijuana after a personal consultation with the patient. The decision on strain selection lies solely with the doctor; the patient cannot independently change the raw material.

The doctor analyzes the medical history, current medications, contraindications (e.g., psychotic disorders, pregnancy, severe liver failure), and interactions. The patient presents symptoms, expectations, and preferences regarding the form. Together, they establish a therapeutic plan.

What to expect from the doctor

• A full interview, not just writing symptoms on the prescription.
• An explanation of why the chosen strain and not another.
• A written titration scheme.
• A rotation plan (when to change the strain).
• Contact in case of adverse effects.

Red flags in the office

A doctor who issues a prescription without an interview, without examination, and without explaining the strain selection acts unprofessionally. An Rpw prescription is a medical document as important as a prescription for morphine, not a commodity for online sale without contact with the patient.

What to do when the strain doesn't work?

According to clinical studies, about 25-30% of patients on their first selected strain do not achieve a satisfactory therapeutic effect, as confirmed by observations from Health Canada and the German BfArM. The lack of effect does not mean that cannabinoid therapy "does not work."

Three decision paths are possible, and each requires consideration with a doctor. Independently increasing the dose is the most common mistake of patients disappointed with the first attempt.

Path 1: Change the strain

Indicated when the chemovar does not match the indication (e.g., you received sativa for insomnia). The doctor prescribes a strain with a different terpene profile or a different THC:CBD ratio. The most common scenario for anxiety, depression, sleep.

Path 2: Increase the dose

Indicated when the strain has the right profile, but the dose is subtherapeutic. Gradually increase by 1-2 mg THC/administration until the effect or threshold of adverse effects is achieved. The maximum daily dose is determined by the doctor.

Path 3: Reassess the indication

Indicated when neither changing the strain nor the dose helps. It may turn out that the pain is not neuropathic but nociceptive, that insomnia results from untreated depression, or that "anxiety" is a symptom of thyroid disease. The primary diagnosis may need to be expanded.

From our observations, patients often choose path 2 (increase the dose) when they actually need path 1 (change the strain). Increasing the THC dose without changing terpenes rarely improves the effect; more often, it only intensifies adverse effects.

Polish legal context: what does the patient's path look like?

Medical marijuana in Poland operates under the amendment to the Act of July 29, 2005, on counteracting drug addiction, which came into force on November 1, 2017 (ISAP, Journal of Laws 2005 No. 179 item 1485). Raw material is only dispensed on an Rpw prescription in licensed pharmacies.

The patient's path consists of four steps: consultation with an authorized physician, receiving an Rpw prescription (paper or e-prescription), finding a licensed pharmacy (about 800 facilities in PL, 2026), and filling the prescription.

Key formal requirements

• Rpw prescription valid for 30 days from the date of issuance.
• The doctor issues it after a personal consultation, not online "anonymously."
• The current list of registered raw materials is available at pacjent.gov.pl and gov.pl/web/zdrowie.
• No reimbursement from NFZ except for Sativex in strict indications (individual reimbursement).
• The maximum monthly dose on the prescription is determined by the doctor, usually 30-60 g of flower.

What to avoid

So-called "teleprescriptions" issued without a personal examination are legally questionable practices. A prescription must be preceded by a medical interview and assessment of documentation. A patient using the services of an "online cannabis clinic" should require a video consultation with access to medical records.

The Polish medical marijuana market has been operating since November 1, 2017, based on the amendment to the Act of July 29, 2005, on counteracting drug addiction. Raw material is only dispensed on an Rpw prescription issued by an authorized physician after a personal consultation. The current list of registered raw materials is published at pacjent.gov.pl (ISAP, 2017).

step-by-step guide to the Polish procedure

How does medical marijuana differ from over-the-counter CBD products?

Medical marijuana contains psychoactive THC above 0.3% and requires an Rpw prescription. CBD products legally available in cannabis shops contain THC below 0.3% and do not require a prescription, but do not replace medical therapy in conditions qualifying for Rpw.

WHO ECDD confirmed in 2018 that pure CBD does not exhibit addictive potential or significant adverse psychotropic effects (WHO ECDD, 2018). This opens CBD to supportive rather than substitute applications.

When is CBD sufficient?

• Mild everyday stress, prevention of tension.
• Support for sleep during overload periods, not chronic insomnia.
• Alleviating muscle tension after exertion.
• Supplementation for individuals avoiding THC for professional reasons.

When is an Rpw prescription needed?

Any serious clinical indication: chronic pain requiring opioids, drug-resistant epilepsy, MS spasticity, chemotherapy-induced nausea, cachexia anorexia, severe PTSD. Over-the-counter CBD does not replace medical therapy in these indications.

Frequently Asked Questions (FAQ)

Can I choose a medical marijuana strain in the pharmacy myself?

No. Each strain requires an Rpw prescription issued by a doctor after a personal consultation, containing the name of the specific raw material, dose, and method of use. The pharmacist will not dispense a different strain than indicated on the prescription. However, the patient can co-decide with the doctor by discussing their preferences regarding the form (flower, oil) or terpene profile.

How long does it take to find the right strain?

According to clinical observations, about 60-70% of patients achieve a satisfactory effect after 2-4 weeks of titrating the first selected strain. The remaining 25-30% require a change of raw material or dose, which extends the process to 8-12 weeks. Patience and keeping a dosing journal are key (CAVITY, 2015).

Do THC-dominant strains cause addiction?

According to NASEM, the risk of cannabinoid addiction is 9% for regular users and 17% for those starting in adolescence (US, 2017). The risk is lower than for opioids (15-30%) or alcohol (15%). Using under medical supervision and with dose titration further reduces this risk.

Can I drive a car while on medical marijuana?

No. THC present in the body is treated under Polish road traffic law like any other narcotic, regardless of whether used on prescription. CBD-dominant strains with THC below 0.2% and Sativex in strictly controlled doses may be exceptions after consultation with a doctor. The patient must consider the legal risk.

What is the difference between indica, sativa, and hybrid?

The classic indica/sativa division is now considered oversimplified. Lewis et al. proposed a classification of chemovars I, II, III based on the cannabinoid profile (Molecules, 2018). Indica associated with sedation and sativa with stimulation are marketing shortcuts, not pharmacological classifications. The chemical profile (THC, CBD, terpenes) matters, not the label.

Can medical marijuana be combined with other medications?

Yes, but it requires medical supervision. Cannabinoids are metabolized by cytochrome P450 (CYP3A4, CYP2C9), which leads to interactions with warfarin, clobazam, some antidepressants, and opioids. Whiting et al. emphasize the need to monitor interactions in polypharmacy patients (CAVITY, 2015). Never combine on your own.

Is there a "best" strain of medical marijuana?

No. The "best" strain depends on the indication, patient profile, tolerance, and preferred method of administration. What works perfectly for one patient with neuropathic pain may increase anxiety in another with PTSD. The 4-step framework (indication, cannabinoids, terpenes, form) replaces the question of "the best brand" with the question of "the best-matched chemovar."

What to do when the pharmacist says the strain is unavailable?

Contact the attending physician and request an equivalent with a similar chemical profile based on the equivalents table from this article. The doctor will issue a new Rpw prescription with a different raw material of a similar chemovar. You can also check availability at another licensed pharmacy through the GdziePoLek app.

Does over-the-counter CBD work the same as CBD from the pharmacy on Rpw?

The chemical profile of pure CBD is the same, but standardization, GMP certification, and batch control may differ. Pharmacy CBD in strains like Bedrolite or Aurora 0:1 has full pharmaceutical documentation. CBD from a cannabis shop should have the manufacturer's COA and a declaration of THC below 0.3%. For clinical indications, always prefer pharmacy raw material.

How long does the effect of a single dose last?

Flower for vaporization: 2-4 hours. Sublingual oil: 4-8 hours. Standardized capsules: 6-8 hours. Edibles: 6-12 hours. Differences arise from pharmacokinetics, which NASEM discusses in detail in its 2017 report (US, 2017). When establishing daily dosing, plan administrations according to this profile.

Summary: 4-step framework instead of asking about the brand

Choosing a medical marijuana strain ceases to be a lottery when you apply the 4-step framework: determine the indication, select the THC:CBD ratio, match the terpene profile, choose the method of use. The manufacturer's brand is secondary if the chemovar fits the clinical need.

The decision should always be made in the office of a physician authorized to issue Rpw prescriptions, based on a full interview and analysis of the medical history. The patient as an active partner: keeps a dosing journal, reports adverse effects, discusses rotations, checks availability of equivalents. This is how modern cannabinoid therapy works.

If you are preparing for your first consultation, write down answers to four questions: what symptoms do I want to alleviate, what time do they intensify, do I need to function professionally, what medications am I taking. This information shortens the path to a well-matched strain by weeks. For general tension and sleep support (beyond indications requiring Rpw), you may consider over-the-counter CBD products.

category of hemp oils and flowers

Medical disclaimer: Medical marijuana in Poland requires an Rpw prescription issued by an authorized physician after a personal consultation. The content of the article is for educational purposes only and does not replace medical advice. Always consult the choice of strain, dose, and form with your attending physician. Do not change the raw material prescribed on the prescription independently. CBD products available in cannabis shops contain THC below 0.3% (legal in PL) and do not replace medical therapy. The current list of registered medical marijuana raw materials is available at pacjent.gov.pl and gov.pl/web/zdrowie.